Barclays PLC Abeona Therapeutics Inc. Transaction History

Barclays PLC

$436 Billion
Q2 2025

A detailed history of Barclays PLC transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 76,401 shares of ABEO stock, worth $417,913. This represents 0.0% of its overall portfolio holdings.

Number of Shares

76,401

Previous 76,401 -0.0%

Holding current value

$417,913

Previous $434,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$4.18 - $7.0 $34,961 - $58,548	-8,364 Reduced 9.87%	76,401 $434,000
Q1 2025 May 15, 2025	BUY	$4.76 - $6.02 $136,369 - $172,466	28,649 Added 51.05%	84,765 $403,000
Q4 2024 Feb 13, 2025	BUY	$5.55 - $6.67 $6,193 - $7,443	1,116 Added 2.03%	56,116 $313,000
Q3 2024 Nov 15, 2024	SELL	$4.12 - $6.32 $88,143 - $135,210	-21,394 Reduced 28.0%	55,000 $348,000
Q2 2024 Aug 14, 2024	BUY	$3.17 - $8.05 $63,400 - $161,000	20,000 Added 35.46%	76,394 $324,000
Q1 2024 May 15, 2024	SELL	$4.07 - $8.68 $461,285 - $983,773	-113,338 Reduced 66.77%	56,394 $409,000
Q4 2023 Feb 15, 2024	SELL	$3.71 - $5.14 $747,728 - $1.04 Million	-201,544 Reduced 54.28%	169,732 $850,000
Q3 2023 Nov 07, 2023	BUY	$2.98 - $4.43 $553,201 - $822,376	185,638 Added 100.0%	371,276 $1.56 Million
Q4 2022 Feb 13, 2023	BUY	$2.4 - $5.65 $436,747 - $1.03 Million	181,978 Added 4972.08%	185,638 $572,000
Q3 2022 Nov 03, 2022	BUY	$2.79 - $5.56 $10,211 - $20,349	3,660 New	3,660 $11,000

Others Institutions Holding ABEO

# of Institutions

103

Shares Held

31.5M

Call Options Held

2.42M

Put Options Held

212K

View Full List

About ABEONA THERAPEUTICS INC.

Ticker ABEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,950,380
Market Cap $32.5M
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...

More about ABEO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account